Nuvectis Pharma Company Insiders
| NVCT Stock | USD 9.35 0.39 4.35% |
Nuvectis Pharma's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Nuvectis Pharma suggests that vertually all insiders are extremely bullish. Nuvectis Pharma employs about 13 people. The company is managed by 4 executives with a total tenure of roughly 31 years, averaging almost 7.0 years of service per executive, having 3.25 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2025-02-07 | Marlio Charles Mosseri | Acquired 240000 @ 5 | View | ||
| 2024-12-24 | Ron Bentsur | Acquired 4500 @ 4.65 | View | ||
| 2024-12-13 | Marlio Charles Mosseri | Acquired 17000 @ 4.7 | View | ||
| 2024-11-19 | Enrique Poradosu | Acquired 2000 @ 4.99 | View | ||
| 2024-11-15 | Ron Bentsur | Acquired 20000 @ 4.92 | View | ||
| 2024-05-14 | Ron Bentsur | Acquired 1940 @ 6.74 | View | ||
| 2024-05-10 | Ron Bentsur | Acquired 2000 @ 6.4 | View |
Monitoring Nuvectis Pharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Nuvectis |
Nuvectis Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.6565) % which means that it has lost $0.6565 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7341) %, meaning that it created substantial loss on money invested by shareholders. Nuvectis Pharma's management efficiency ratios could be used to measure how well Nuvectis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.07 in 2025. Return On Capital Employed is likely to drop to -1.77 in 2025. Change To Liabilities is likely to gain to about 5 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 5.4 M in 2025.Common Stock Shares Outstanding is likely to drop to about 15.6 M in 2025. Net Loss is likely to gain to about (16.3 M) in 2025
Nuvectis Pharma Workforce Comparison
Nuvectis Pharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,663. Nuvectis Pharma maintains roughly 13.0 in number of employees contributing less than 1% to equities under Health Care industry.
Nuvectis Pharma Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nuvectis Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nuvectis Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Nuvectis Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 6.0 | 6 | 1 | 92,621 | 2,755 |
| 2022-03-01 | 1.7143 | 12 | 7 | 267,546 | 0.00 |
Nuvectis Pharma Notable Stakeholders
A Nuvectis Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nuvectis Pharma often face trade-offs trying to please all of them. Nuvectis Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nuvectis Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Shay Shemesh | Executive CoFounder | Profile | |
| Enrique Poradosu | Executive CoFounder | Profile | |
| Michael CPA | Vice Finance | Profile | |
| Ron MBA | Chairman, CoFounder | Profile |
About Nuvectis Pharma Management Performance
The success or failure of an entity such as Nuvectis Pharma often depends on how effective the management is. Nuvectis Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nuvectis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nuvectis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (1.69) | (1.77) | |
| Return On Assets | (1.02) | (1.07) | |
| Return On Equity | (1.96) | (2.05) |
Please note, the imprecision that can be found in Nuvectis Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nuvectis Pharma. Check Nuvectis Pharma's Beneish M Score to see the likelihood of Nuvectis Pharma's management manipulating its earnings.
Nuvectis Pharma Workforce Analysis
Traditionally, organizations such as Nuvectis Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nuvectis Pharma within its industry.Nuvectis Pharma Manpower Efficiency
Return on Nuvectis Pharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 4.8M | |
| Working Capital Per Employee | 747.2K | |
| Working Capital Per Executive | 2.4M |
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.